Early differentiation work focused on the anti-proliferative properties of the repurposed anti-cancer drug DL-α-difluoromethylornithine (DFMO), a specific irreversible inhibitor of the enzyme responsible for catalysing the first reaction in the polyamine biosynthesis pathway, ornithine decarboxylase (ODC) [73,74]. Here, ODC1 is linked to cancer.